Matthew Peterson to support trial quality and completion. Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and ...

An international team of researchers has provided a genetic diagnosis for 30 individuals whose condition was undiagnosed for years despite extensive ...

A multi-institutional study made up of 26 researchers led by the University of Melbourne has discovered that iron-reducing ...

Because of that, they wanted to see whether its multi-kinase inhibition might lead to meaningful effects on MS disease course ...

A randomised clinical trial found that reduced iron may accelerate cognitive decline in early-stage Alzheimer’s disease.

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system.

The brain, traditionally considered an immune-privileged organ due to the blood-brain barrier (BBB), has its own sophisticated immune defense system.

“This new study provides real-world evidence for its impact on Alzheimer’s disease, even though preclinical research has suggested that semaglutide may protect against neurodegeneration and ...